Replies to post #8871 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>rituxan is on patent until 2017<

There are various US patents related to Rituxan. GTC believes that, for companies seeking to commercialize CD20 mAbs in the US, the patent of consequence expires in 2014.

[DewDiligence]

Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.